Paul E. Marik MD (2025)

13/07/2025

Message me privately for a parasitic detoxification protocol

10/07/2025

We won’t be silenced. Keep sharing.

04/07/2025

ARTICLE: Could High-Dose Melatonin Support the Body During Challenging Health Conditions? A Look at Emerging Research

Melatonin is widely known as a natural sleep aid, but new research is exploring its potential role in supporting the immune system and helping the body manage serious health challenges, including certain forms of cancer.

What the Research Suggests

In recent peer-reviewed studies, melatonin has shown promising effects such as:
• Modulating immune system function
• Supporting the body’s natural defenses against abnormal cell growth
• Enhancing the tolerability of chemotherapy and radiation
• Regulating microRNAs — small RNA molecules that influence gene expression related to tumor suppression and growth

MicroRNAs (miRNAs) play a key role in cellular processes. Some studies indicate melatonin may help balance miRNAs associated with cancer development — by promoting those that suppress tumors and reducing activity of those linked to unchecked cell growth.

Why This Matters Now

There is growing interest in how melatonin interacts with the body’s regulatory systems — especially in light of health concerns being studied post-pandemic. Some researchers are exploring whether melatonin could support health in individuals experiencing aggressive or fast-progressing cancer. More rigorous, large-scale research is needed.

High-Dose Use in Clinical Settings

Typical melatonin supplements range from 1–10mg. However, in experimental or clinical contexts, much higher doses — such as 50mg or more — have been explored under medical supervision. These are not general-use recommendations but part of carefully monitored therapeutic trials.

Delivery Methods

Melatonin has certain absorption limitations. New delivery systems — including nano-formulations — are being studied to improve its availability in the body.

⸻

Conclusion:
Melatonin’s role in health may go well beyond sleep. Current research into its potential to assist in cancer care is ongoing, and while early findings are encouraging, anyone considering high-dose melatonin should consult a healthcare provider. The science is evolving — and worth watching.

*for educational purposes.

27/06/2025

NEW ARTICLE: IVERMECTIN and MEBENDAZOLE Testimonial - 57 year old man with Stage 4 Colorectal Cancer (TURBO CANCER) sees dramatic improvement in 3 months! CEA drops from 96 to 3.3, liver metastasis shrinks 88%

All of these successes are going to be published one day! 😃

Today's Ivermectin success story is Stage 4 Colorectal Cancer.

STORY:

57 year old man with Stage 4 Colorectal Cancer metastatic to liver

"my beloved husband is 57 years old and just diagnosed with Stage 4 Colon and liver cancer. A doctor told us he is inoperable and incurable...the only thing i can attribute this to is that stupid vaccination"

They reached out to my Ivermectin Cancer Clinic in January 2025

He started 120mg Ivermectin and 1000mg Mebendazole on Jan.13, 2025, along with chemo on Jan.19, 2025.

After exactly 3 months:

CEA dropped from 96 to 48 to 16.9 to 7.1 to 5.0 to 3.3 (normal)

“Oncologist was extremely surprised” by the dramatic drops in CEA

3.6cm Liver segment II metastasis shrunk to 1.8cm (87.5% shrinkage in tumor volume, according to Grok-3)

Always look for the Oncologist’s surprised reactions which will tell you what can be attributed to the chemo and what can be attributed to Ivermectin, Fenbendazole or Mebendazole.

No one can stop the coming revolution in Cancer Care and I am here for it. 😃

Thousands of Cancer patients from around the world are benefiting right now!!

25/06/2025

From Stage 4 to Cancer-Free: A Mother’s Journey Through Aggressive Cancer and Unconventional Hope

One of the most unforgettable patients I’ve had the privilege to work with through my Telehealth cancer clinic is the woman you see in these photos. She’s a 35-year-old mother who came to me after being diagnosed in November 2023 with an aggressive form of Stage 4 triple-positive breast cancer. By the time we connected, the cancer had already spread to her lungs, spine, and sternum. She’d been told by her oncologists that she had very little time left—and that there were no more viable treatment options.

Her story hit me deeply—not only because of how young she was but because of the life she still had left to live. The little girl beside her in the photos is her daughter, and every step of her fight was for her.

Both she and her husband had received their full COVID-19 mRNA vaccination series, including boosters, shortly before their diagnoses—hers being breast cancer, his testicular cancer. Based on what I’ve seen across many cases, I strongly suspected this was another example of what I refer to as “vaccine-induced turbo cancer.”

Despite resistance from her traditional oncology team, she made the brave decision to work with me and began my intensive protocol in mid-August 2024. I put her on a high-dose regimen:
• Ivermectin: starting at 1mg/kg/day, increasing to 2mg/kg/day
• Mebendazole: 1500mg/day

I’ve always believed that aggressive cancers require an equally aggressive, targeted approach—especially when conventional medicine has already given up.

Six months later, her PET/CT scan showed the kind of results that remind me why I do this work. The report read:

“Excellent treatment response with interval left mastectomy as well as complete resolution of FDG avid bone metastasis and bilateral hilar FDG avid lymph nodes that were present on prior exam. No findings to suggest active malignant disease at this time.”

She was told she had little time to live. Now, she’s cancer-free and making memories with her daughter again.

I know cases like this challenge mainstream thinking—and that’s why my work comes under constant scrutiny. But the photos speak louder than words. This is a mother who got her life back, and a daughter who still has her mom.

This is why I keep fighting—and why I’ll never stop offering hope to those the system has written off.

22/06/2025

NEW ARTICLE: IVERMECTIN and MEBENDAZOLE - 74 year old Canadian man with Glioblastoma gives an exciting update after 3 months!

Do you want to hear a brain cancer success story? 😃
Of course you do!

74 year old Canadian man with Glioblastoma

In early March 2025 we started:

Ivermectin 1.5mg/kg/day
Mebendazole 1500mg/day
CBD Oil 100mg/day

The patient was on this regimen for 3 months (and if you count the Ivermectin and Fenbendazole they started on their own in early February, then 4 months).

From the patient:

"he recently had his first MRI since chemo and radiation begun
- there were no abnormal changes
- no abnormalities
- no new artifacts

Overall, both our family and the oncologists were extremely happy to not see any visible growth or changes."

"First off, thank you for your work and services, I have zero doubt that the results would have been different if we didn’t have your guidance."

.

I do believe that Glioblastoma recurrence could be eliminated with a repurposed drug regimen that includes Ivermectin and Mebendazole.

Of course, now we have to prove it with long term follow-up and publish it.

Remember, this patient was quoted a life expectancy as low as 6 months as Glioblastomas are notorious for recurrence despite best conventional cancer treatment.

We are 4 months in and the patient is CANCER FREE.

Ps/ not my client’s testimony

21/06/2025

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer

We show that treatment with the FDA-approved anti-parasitic drug ivermectin induces immunogenic cancer cell death (ICD) and robust T cell infiltration into breast tumors. As an allosteric modulator of the ATP/P2X4/P2X7 axis which operates in both cancer and immune cells, ivermectin also selectively targets immunosuppressive populations including myeloid cells and Tregs, resulting in enhanced Teff/Tregs ratio. While neither agent alone showed efficacy in vivo, combination therapy with ivermectin and checkpoint inhibitor anti-PD1 antibody achieved synergy in limiting tumor growth (p = 0.03) and promoted complete responses (p < 0.01), also leading to immunity against contralateral re-challenge with demonstrated anti-tumor immune responses. Going beyond primary tumors, this combination achieved significant reduction in relapse after neoadjuvant (p = 0.03) and adjuvant treatment (p < 0.001), and potential cures in metastatic disease (p < 0.001). Statistical modeling confirmed bona fide synergistic activity in both the adjuvant (p = 0.007) and metastatic settings (p < 0.001). Ivermectin has dual immunomodulatory and ICD-inducing effects in breast cancer, converting cold tumors hot, thus represents a rational mechanistic partner with checkpoint blockade.

20/06/2025

New Observational Report: Ivermectin and Cognitive Decline — Anecdotal Accounts in Dementia and End-of-Life Care

A series of six compelling case reports suggests that Ivermectin may have potential off-label benefits in patients experiencing various forms of cognitive decline, including vascular dementia, Alzheimer’s disease, and terminal-stage dementia. These unverified personal testimonials, while not part of a controlled clinical study, highlight notable improvements in patient behavior, cognition, and quality of life following administration of Ivermectin.

Case 1: Vascular Dementia
A patient with vascular dementia reportedly showed marked behavioral improvement within one week of Ivermectin use. Family members observed reduced agitation and a more cooperative, calm demeanor.

Case 2: Alzheimer’s Dementia
An 84-year-old woman with Alzheimer’s experienced improved sleep patterns—sleeping through the night during the five days she was administered 12 mg of Ivermectin daily—contrasting with her prior nocturnal restlessness.

Case 3: Cognitive Decline at End-of-Life
An 82-year-old man with severe cognitive decline showed dramatic improvement in mental clarity, conversational ability, energy, and appetite following Ivermectin initiation. His condition improved to the extent that hospice care was withdrawn.

Case 4: New-Onset Dementia
A 93-year-old woman with new cognitive symptoms reportedly returned to her previous mental baseline within 48 hours of starting a daily dose of 24 mg. Family members described the change as “stark” and uncharacteristically rapid.

Case 5: Advanced Dementia in a 97-Year-Old
This patient, previously unresponsive and unable to recognize family, received 24 mg of Ivermectin and was reportedly sitting up, eating, and engaging in meaningful conversation the following day. His cognitive function continued to improve daily.

Case 6: Memory Loss in an 82-Year-Old (Brazil)
Mild improvements in vocabulary, time orientation, and emotional recognition were noted following daily administration of 24 mg of Ivermectin, suggesting possible benefits in earlier cognitive decline.

Conclusion
These six anecdotal cases present intriguing observations that warrant further investigation into the potential neurocognitive benefits of Ivermectin. While not a substitute for clinical trials or evidence-based guidelines, the reported improvements raise important questions and may merit consideration for future research. Ivermectin, under appropriate supervision, could represent a novel adjunct in the symptomatic management of certain neurodegenerative conditions.

19/06/2025

Ivermectin

18/06/2025

Ivermectin Testimonial: 45-Year-Old Swedish Man Sees 70% Tumor Reduction in One Month

At my live event on March 11 in Gothenburg, Sweden, a 45-year-old Swedish man shared his recent experience. He had been diagnosed with a new lung mass measuring 5.5 cm. After starting Ivermectin, just one month later, scans showed the tumor had shrunk to 3.5 cm—a 70% reduction in volume, according to GROK analysis.

Because the tumor was shrinking, doctors decided not to biopsy it, unsure whether it was even malignant—unaware that Ivermectin was involved.

What’s even more remarkable is that this patient hadn’t yet begun my full cancer protocol.

The message here?
Don’t wait. Too many people delay starting because of fear or misinformation about Ivermectin, Fenbendazole, or Mebendazole. They ask:
• “Is it safe?”
• “Will it affect my liver?”
• “Isn’t that just for animals?”
• “I’ve heard negative stories…”

But by waiting, you might miss the chance for a response like this.

I run a large telehealth clinic focused on cancer support with repurposed medicines, and stories like this come in regularly. The potential is real—if you take the first step.

For educational purposes.

15/06/2025

Ivermectin and Mebendazole Testimonial – 53-Year-Old Man in the USA with Advanced Lung Cancer

A 53-year-old American man with advanced non-small cell lung cancer (NSCLC) that had spread to his lymph nodes, adrenal glands, and brain had been on Keytruda since April 2024. At the end of January 2025, we added:
• Ivermectin at a dose based on body weight (1.5 mg per kg daily)
• Mebendazole at 1000 mg per day

Just over a month later, a follow-up PET scan showed:
• Almost complete disappearance of the previously active cancer in his chest lymph nodes
• The adrenal tumors no longer showed signs of aggressive activity

These changes were seen after starting Ivermectin and Mebendazole.

My Perspective…
I say this to my new patients all the time, not all patients who come to me are worsening. Some are already seeing some benefit from traditional treatments like chemotherapy, radiation, or immunotherapy.

This is where Ivermectin, Mebendazole, and even Fenbendazole can make a huge difference. They don’t just attack cancer cells directly—they also seem to make chemotherapy and radiation more effective by making cancer cells more sensitive to those treatments.

14/06/2025

Ivermectin and fenbendazole

Paul E. Marik MD